Abstract: Disclosed are anti-CD45 antibodies and antibody drug conjugates (ADCs) useful in therapeutic methods, including targeting CD45 expressing hematopoietic stem cells (HSCs) or immune cells prior to transplantation.
Type:
Grant
Filed:
April 29, 2021
Date of Patent:
May 6, 2025
Assignee:
Vor Biopharma Inc.
Inventors:
Rahul Palchaudhuri, Bradley R. Pearse, Hillary Adams, Sean McDonough, Michael Cooke, Anthony Boitano
Abstract: Disclosed is a method for vaccination against a self-antigen in a human patient wherein a dose with an effective amount of a self-antigen is administered to the patient to elicit a primary immune response, characterised in that the patient is subjected to a boost administration of said self-antigen, wherein the amount of the self-antigen in the dose for the boost administration is higher than the amount of the self-antigen in the dose used in the administration for the primary immune response.
Type:
Grant
Filed:
November 2, 2016
Date of Patent:
May 6, 2025
Assignee:
AC Immune SA
Inventors:
Gergana Galabova, Sabine Schmidhuber, Achim Schneeberger, Arne Von Bonin, Dorian Winter, Jana Zimmermann
Abstract: The present invention provides antibody compounds that contain a substitution of arginine for the reactive lysine residue (Lys99) in the hydrophobic cleft (38C2_Arg). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered arginine residue in the 38C2_Arg variant antibody. Further provided in the invention are therapeutic applications of the compounds.
Type:
Grant
Filed:
October 8, 2019
Date of Patent:
April 29, 2025
Assignee:
University Of Florida Research Foundation, Incorporated
Inventors:
Christoph Rader, Dobeen Hwang, Napon Nilchan
Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
Type:
Grant
Filed:
February 14, 2020
Date of Patent:
April 29, 2025
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Richard Brokx, Jacqueline M. Mason, Mark R. Bray
Abstract: A composition of matter comprising an extract of a plurality of seeds of an edible plant of interest is disclosed. Use of the composition and methods of generating same are also disclosed.
Type:
Grant
Filed:
January 16, 2019
Date of Patent:
April 22, 2025
Assignees:
Tel HaShomer Medical Research Infrastructure and Services Ltd., The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center)
Abstract: The present application provides single-domain antibodies targeting CD33 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune cells (such as T cells) comprising an anti-CD33 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
Abstract: The present invention relates to a humanized anti-human OX40 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human OX40 monoclonal antibody provided in the present invention has high affinity and specificity for OX40, and can stimulate T cells to secrete cytokines, for example, specifically activate the positive immune regulation by OX40 and activate T cells to secrete cytokines. Therefore, the functional humanized anti-human OX40 monoclonal antibody provided in the present invention activates T cells by activating the OX40 signaling pathway, thereby achieving the purpose of tumor immunotherapy.
Abstract: The present invention refers to a new site-specific monoclonal antibody for tau protein and its use as a tool in specific biomarkers. It also discloses the process of generating said site-specific monoclonal antibody, and kits for early detection of neurodegenerative diseases and pathologies involved with the tau protein, such as Alzheimer's and other types of dementia.
Type:
Grant
Filed:
May 26, 2022
Date of Patent:
April 8, 2025
Assignee:
CORPORACIÓN CENTRO INTERNACIONAL DE BIOMEDICINA ICC
Abstract: The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (A?) peptides and methods of use thereof.
Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
March 25, 2025
Assignees:
IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE
Inventors:
Etienne Foucher, Carla Cano, Kieu Suong Le, Christine Pasero, Daniel Olive
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
Type:
Grant
Filed:
December 26, 2019
Date of Patent:
March 11, 2025
Assignee:
NEURACLE SCIENCE CO., LTD.
Inventors:
Bongcheol Kim, Dong Sik Kim, Jae-Keun Lee, Juwon Shim
Abstract: Provided are bispecific or multispecific antibodies that include an anti-CEACAM5 portion and one or more anti-4-1BB nanobodies whose agonist activity is dependent on the presence of the CEACAM5 antigen. Such bispecific or multispecific antibodies are safe, and are efficacious in treating cancer and have long-term protective immunological memory against tumors. Methods of using the antibodies for treating diseases such as cancer are also provided.
Abstract: The disclosure provides polypeptides and pharmaceutical compositions thereof. Such polypeptides can be useful, for example, in treating pain in a subject. In some embodiments, the polypeptides are useful for treating neuropathic and/or inflammatory pain.
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
August 30, 2019
Date of Patent:
March 11, 2025
Assignee:
ALECTOR LLC
Inventors:
Patricia Culp, Helen Lam, Wei-Hsien Ho, Leonard G. Presta, Arnon Rosenthal
Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
Type:
Grant
Filed:
January 19, 2024
Date of Patent:
March 11, 2025
Assignee:
Miltenyi Biotec B.V. & Co. Kg
Inventors:
Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.
Type:
Grant
Filed:
March 27, 2024
Date of Patent:
March 4, 2025
Assignee:
Aarhus Universitet
Inventors:
Nick Stub Laursen, Dennis Vestergaard Pedersen, Gregers Rom Andersen, Steffen Thiel, Alessandra Zarantonello, Rasmus Kjeldsen Jensen, Henrik Pedersen
Abstract: The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation.
Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.
Type:
Grant
Filed:
February 20, 2020
Date of Patent:
February 18, 2025
Inventors:
Olga Vladimirovna Britanova, Dmitry Borisovich Staroverov, Anna Valentinovna Evstrateva, Alexey Konstantinovich Misorin, Timofey Aleksandrovich Nemankin, Mariia Aleksandrovna Shchemeleva, Anna Konstantinovna Vladimirova, Arina Vitalevna Anikina, Roman Alekseevich Ivanov, Dmitry Valentinovich Morozov, Pavel Andreevich Iakovlev, Sergey Anatolievich Lukyanov
Abstract: The present invention provides an anti-ox40 antibody, an antigen-binding fragment thereof, and the pharmaceutical use. Further, the present application provides a chimeric antibody and a humanized antibody, the chimeric antibody and the humanized antibody comprising a CDR region from the anti-OX40 antibody and the antigen-binding fragment thereof, and also provides a pharmaceutical composition comprising the anti-OX40 antibody and the antigen-binding fragment thereof, and the use thereof as a drug for treating cancers.
Abstract: The present invention relates to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
Type:
Grant
Filed:
October 9, 2019
Date of Patent:
January 28, 2025
Assignee:
Numab Therapeutics AG
Inventors:
Tea Gunde, Matthias Brock, Christian Hess, Alexandre Simonin, Stefan Warmuth